Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Operating Leases (2019 - 2025)

Seres Therapeutics' Operating Leases history spans 6 years, with the latest figure at $103.3 million for Q1 2024.

  • For Q1 2024, Operating Leases changed N/A year-over-year to $103.3 million; the TTM value through Mar 2024 reached $103.3 million, changed N/A, while the annual FY2023 figure was $105.7 million, 2.06% down from the prior year.
  • Operating Leases for Q1 2024 was $103.3 million at Seres Therapeutics, down from $105.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $107.9 million in Q4 2022 and bottomed at $9.2 million in Q1 2021.
  • The 5-year median for Operating Leases is $14.4 million (2020), against an average of $41.9 million.
  • The largest annual shift saw Operating Leases tumbled 36.35% in 2021 before it skyrocketed 501.08% in 2022.
  • A 5-year view of Operating Leases shows it stood at $10.6 million in 2020, then skyrocketed by 70.04% to $18.0 million in 2021, then surged by 501.08% to $107.9 million in 2022, then dropped by 2.06% to $105.7 million in 2023, then dropped by 2.25% to $103.3 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Operating Leases are $103.3 million (Q1 2024), $105.7 million (Q4 2023), and $106.7 million (Q2 2023).